Abstracts tagged "practice improvement"

Abstract Number: 086 • 2020 Pediatric Rheumatology Symposium
Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis
Julia Brooks¹, Dorothy Adams ², Robin Hellweg ¹, Maggie Mercer ¹, Joni Shair ², Dwaraka Veeramreddy ³, Aynsley Wennberg ¹ and Heinrike Schmeling ⁴, ¹Alberta Children's Hospital, Calgary, Alberta, Canada, ²Alberta Children's Hospital, Calgary, Canada, ³Alberta Children's Hospital/University of Calgary, Calgary, Canada, ⁴Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Many patients are overwhelmed with the diagnosis of chronic childhood arthritis and require long-term treatments. Our objective was to develop a new, child and…
Abstract Number: 1265 • 2018 ACR/ARHP Annual Meeting
The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
Lisa K. Stamp¹, Peter T. Chapman², Ben Hudson³, Greg Hamilton⁴ and Andrea Judd⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴Canterbury District Health Board, Christchurch, New Zealand, ⁵Kaikoura Medical Centre, Kaikoura, New Zealand
Background/Purpose: The majority of gout management occurs in primary care and may be suboptimal. While community based clinical trials have reported improvements whether such improvements…
Abstract Number: 3214 • 2016 ACR/ARHP Annual Meeting
Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative
Daniel H. Solomon¹, Bing Lu², Elena Losina³, Jen Agosti⁴, Agnes Zak⁵, Cassandra Corrigan⁵, Zhi Yu⁶, Sara Lee⁵, Asaf Bitton⁷, LR Harrold⁸, Theodore Pincus⁹, Helga Radner¹⁰, Josef Smolen¹¹, Liana Fraenkel¹² and Jeffrey N. Katz¹³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴JRA Consulting, Andover, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Medicine, Brigham and Women's Hospital, Boston, MA, ⁸University of Massachusetts Medical School, Worcester, MA, ⁹Rheumatology, Rush University Medical Center, Chicago, IL, ¹⁰Rheumatology, Medical University of Vienna, Vienna, Austria, ¹¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹²Yale University School of Medicine, New Haven, CT, ¹³Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but various studies suggest that its uptake in routine…
Abstract Number: 2489 • 2015 ACR/ARHP Annual Meeting
Effects of Two Interventions on Rheumatologists Adherence to Optimal Care Recommendations in Rheumatoid Arthritis: A Combined before/after and Randomized Controlled Trial
Nienke Lesuis¹, Ronald van Vollenhoven², Marlies Hulscher³ and Alfons den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³IQ Healthcare, Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend using tight control strategies.1 Despite evidence for the benefits of this strategy, physician adherence is suboptimal.2,3…
Abstract Number: 2365 • 2014 ACR/ARHP Annual Meeting
Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept
Richard Martin¹, Ryan Enck², Andrew J. Head³, James Birmingham¹ and Aaron T. Eggebeen⁴, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University College of Human Medicine, Grand Rapids, MI, ³Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ⁴Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: To evaluate the comparative effects of a pharmaceutical industry decision guide (Pharm Booklet) and International Patient Decision Aids Standard (IPDAS) compliant patient decision aids…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].